At a glance
ClinicalIndex Comparison RecordN/ACompleted· 7,972 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Humira 40 mg/0.8 mL for Subcutaneous Injection - Drug Use Investigation (All Patient Investigation) for Rheumatoid Arthritis
In Brief
An observational study for Rheumatoid Arthritis. Completed, enrolled 7,972 participants across 1,723 sites.
Detailed Summary
To clarify the following matters: * Unknown adverse reactions (especially clinically significant adverse reactions) * Incidence and conditions of occurrence of adverse reactions in the clinical setting * Factors that may affect the safety and effectiveness of Humira
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedFeb 2010
Primary CompletionJun 2011
TodayJul 2026
First PostedFeb 26, 2010
Enrollment StartJun 1, 2008
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 16.3 years ago